Clinical trials: Malaria Transmission
Malaria, Malaria Vaccines
Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa
This epidemiology study was conducted in parallel with the EPI-MAL-002 (NCT02374450) and EPI-MAL-003 (NCT03855995) studies, enrolling participants from the same health and demographic surveillance system (HDSS) (or equivalent…
- Trial name
- NCT02251704
- Testing
- Assessment of body temperature, Blood sampling
- Where
- 12 sites in Burkina Faso, Ghana and 4 more
- Volunteers
- 54,115 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV, Pregnancy Malaria
A Novel Regimen to Prevent Malaria and STI in Pregnant Women With HIV
More than 3 billion people worldwide are at risk of acquiring malaria and pregnant women living with HIV in Africa are at particular risk.
- Conditions
- HIV, Pregnancy Malaria, Sexually Transmitted Infection
- Trial name
- PREMISE (NCT03431168)
- Testing
- Azithromycin/TMPS
- Where
- United States
- Volunteers
- 308 people
- Sponsor
- University of Alabama at Birmingham
Malaria
Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa
This study is designed to characterise P. falciparum transmission intensity in subjects aged ≥6 months and <10 years by measurement of P.
- Trial name
- NCT01954264
- Testing
- Capillary blood sample, Data collection
- Where
- 3 sites in Burkina Faso, Senegal
- Volunteers
- 2,421 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria, HIV Infections
Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women
This study is an open-label, single site, randomized controlled trial comparing protease inhibitor (PI)-based antiretroviral therapy (ART) to non-PI based ART for HIV-infected pregnant and breastfeeding women of all CD4 cell…
- Trial name
- PROMOTE-PIs (NCT00993031)
- Testing
- Lopinavir/ritonavir, Efavirenz, Zidovudine
- Where
- Uganda
- Volunteers
- 389 people
- Sponsor
- University of California, San Francisco
Malaria
Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali
Background: Researchers are looking for new ways to control and eradicate malaria. They want to test vaccines to block malaria transmission in adults in Mali. These vaccines work by inducing antibodies in a person.
- Trial name
- NCT02942277
- Testing
- Pfs25M-EPA, Pfs230D1M-EPA, AS01
- Where
- Mali
- Volunteers
- 301 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Malaria,Falciparum
Safety and Efficacy of R0.6C Vaccine
This is a first-in-human phase I, open-label, single-site, dose escalation study to determine the safety, tolerability and Plasmodium falciparum transmission reducing activity of the R0.6C vaccine in two different adjuvant…
- Trial name
- STOP-TRANS (NCT04862416)
- Testing
- R0.6C transmission blocking vaccine
- Where
- Netherlands
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Malaria, HIV Infections
HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children
HIV and malaria are major causes of morbidity and mortality in Sub-Saharan Africa and children bear the greatest brunt of both diseases. No single existing intervention is likely to control malaria in Africa.
- Trial name
- PROMOTE-PEDS (NCT00978068)
- Testing
- Lopinavir/Ritonavir (LPV/r), Nevirapine (NVP), Efavirenz (EFV)
- Where
- Uganda
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Malaria
Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Malaria Transmission Season in Healthy African Adult Women of Childbearing Potential in Mali
Background: Malaria is a disease spread by mosquitos. Pregnant women are highly susceptible to malaria. This can lead to poor health outcomes for pregnant women and their babies.
- Trial name
- NCT03989102
- Testing
- PfSPZ Vaccine, Normal Saline
- Where
- Mali
- Volunteers
- 324 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Malaria Vaccines
Epidemiology Study of Malaria Transmission Intensity in Africa
The aim of this epidemiology study is to characterize in a standardized way malaria transmission intensity at the clinical trial centers participating in study 110021 (NCT00866619).
- Trial name
- NCT01190202
- Testing
- Blood sampling, Assessment of body temperature
- Where
- 8 sites in Burkina Faso, Gabon and 4 more
- Volunteers
- 21,618 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Drug-Drug Interaction, HIV Infection
Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy
Open-label prospective intensive pharmacokinetic study of dihydroartemisinin-piperaquine (DP) in HIV-infected children on efavirenz (EFV)-, lopinavir/ritonavir (LPV/r)-, or dolutegravir (DTG)-based antiretroviral therapy (ART)…
- Trial name
- DPART (NCT04487145)
- Testing
- Dihydroartemisinin-piperaquine
- Where
- 2 sites in Uganda
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Malaria,Falciparum
Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in Mali
Background: Researchers are trying to develop a vaccine that will safely reduce the spread of malaria in the community by preventing mosquitos from carrying malaria from person to person.
- Trial name
- NCT05135273
- Testing
- Pfs230D1-EPA/Matrix-M Vaccine, Verorab Rabies Vaccine
- Where
- Mali
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria,Falciparum
Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics of TB31F
This phase 1 study aims to assess the safety and tolerability of monoclonal antibody TB31F administered intravenously or subcutaneously at escalating dose levels in healthy, malaria naïve, adults.
- Trial name
- TB31F (NCT04238689)
- Testing
- TB31F
- Where
- Netherlands
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Malaria
Clinical and Biological Efficacy of Mirasol-treated Fresh Whole Blood for the Prevention of Transfusion-transmitted Malaria
The trial will evaluate the efficacy of the Mirasol Pathogen Reduction Technology for Whole Blood to prevent Malaria transmission by transfusion of whole blood.
- Trial name
- AIMS (NCT02118428)
- Testing
- Mirasol-treated Whole Blood, Untreated Whole Blood
- Where
- Ghana
- Volunteers
- 227 people
- Sponsor
- Terumo BCTbio
Malaria
Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali
Background: The disease malaria affects many people in Mali and other parts of Africa and the world. It is caused by germs spread by mosquito bites. Malaria may be mild.
- Trial name
- NCT03510481
- Testing
- PfSPZ Vaccine, Normal Saline, artemether 20mg/lumefantrine 120mg (AL)
- Where
- Mali
- Volunteers
- 478 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent
This is a single-centre, controlled, open label study using P. falciparum-induced blood stage malaria (IBSM) infection to assess the effectiveness of OZ439 as a gametocytocidal agent, as well as its treatment effects on…
- Trial name
- OZGAM (NCT02431650)
- Testing
- OZ439, Primaquine
- Where
- Australia
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria
Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults
This study is a Phase 1, dose escalation, first-in-human study designed primarily to evaluate the safety of the purified plant-derived Pfs25 VLP combined with Alhydrogel adjuvant
- Trial name
- NCT02013687
- Testing
- Pfs25 VLP- FhCMB
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Fraunhofer, Center for Molecular Biotechnology
Malaria
Experimental Falciparum Transmission to Anopheles
This is a single-centre, open-label study using P. falciparum-induced blood stage malaria (IBSM) infection to assess the infectivity of sexual life cycle stages of the malaria parasite (gametocytes) to mosquito vectors.
- Trial name
- EFITA (NCT02431637)
- Testing
- Administration of the malaria inoculum, Piperaquine Phosphate 480 mg
- Where
- Australia
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria
Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali
Background: Malaria affects many people in Mali and other parts of Africa. It is spread by mosquito bites. Malaria can make people sick or can lead to death.
- Trial name
- NCT03917654
- Testing
- Pfs230D1M-EPA/AS01, HAVRIX, TYPHIM Vi (Salmonella typhi vaccine)
- Where
- Mali
- Volunteers
- 1,301 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Human Immunodeficiency Virus
Reducing the Burden of Malaria in HIV-Infected Pregnant Women and Their HIV-Exposed Children (PROMOTE-BC2)
This is a double-blinded, randomized controlled trial of 200 HIV-infected pregnant women living in Tororo, Uganda, an area of high malaria transmission.
- Trial name
- NCT02282293
- Testing
- Monthly dihydroartemisinin-piperaquine (DP) + daily trimethoprim/sulfamethoxazole (TS)
- Where
- Uganda
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Malaria
Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria
The study is a double-blind, randomized, placebo-controlled, Phase 2 clinical trial that will assess the safety, tolerability, immunogenicity and protective efficacy of PfSPZ Vaccine and PfSPZ-CVac against naturally occurring…
- Trial name
- NCT03503058
- Testing
- PfSPZ Vaccine, PfSPZ Challenge under chloroquine (CQ) chemoprophylaxis, Normal Saline
- Where
- 2 sites in Indonesia
- Volunteers
- 345 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.